STOCK TITAN

Kyverna Therapeutics, Inc. - $KYTX STOCK NEWS

Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: $KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kyverna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kyverna Therapeutics's position in the market.

Rhea-AI Summary
Kyverna Therapeutics, Inc. announces successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells. The company will present a case study at the 2024 annual meeting of the American Academy of Neurology and host a conference call to discuss recent patient experience with KYV-101 in neurological autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
conferences
-
Rhea-AI Summary
Kyverna Therapeutics, Inc. announces successful treatment of two multiple sclerosis patients with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany. The treatment showed an acceptable safety profile, opening doors for larger clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kyverna Therapeutics, Inc. (KYTX) reports strong progress in autoimmune disease treatment with advanced clinical development of KYV-101, securing FDA clearances and Fast Track Designations. The company bolstered its balance sheet with $366.9 million from a recent public offering. Financially, Kyverna reported a net loss of $60.4 million for 2023, with $57.5 million in cash reserves.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
Rhea-AI Summary
Kyverna Therapeutics collaborates with Stanford University to conduct a phase 1 investigator-initiated trial for KYV-101, an anti-CD19 CAR T-cell therapy, in multiple sclerosis patients, aiming to assess safety, feasibility, and tolerance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary
Kyverna Therapeutics, Inc. successfully closed an upsized IPO, raising approximately $366.9 million through the sale of 16,675,000 shares of common stock at $22.00 per share. The company's common stock began trading on the Nasdaq Global Select Market under the symbol 'KYTX'. J.P. Morgan, Morgan Stanley, Leerink Partners, and Wells Fargo Securities acted as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
Kyverna Therapeutics, Inc. announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share, expected to generate gross proceeds of $319.0 million. The company's common stock is set to begin trading on the Nasdaq Global Select Market on February 8, 2024, under the ticker symbol 'KYTX.'
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Kyverna Therapeutics, Inc.

Nasdaq:KYTX

KYTX Rankings

KYTX Stock Data

588.52M
43.12M
Biological Products, (no Disgnostic Substances)
United States of America
EMERYVILLE